Dapagliflozin plus methylcobalamin improved nerve function and glucose control in diabetic neuropathy.

Dapagliflozin is a selective inhibitor of sodium–glucose cotransporter 2 (SGLT2) that blocks glucose resorption in the proximal tubule of the kidney and promotes glucosuria. 11-13 Other SGLT2 ...

Dapagliflozin was stopped for reasons other than death in 249 patients and placebo was stopped in 258 patients (10.5% vs. 10.9%, P=0.71). At the last assessment, ...

Dapagliflozin produces a dose-dependent and sustained reduction in both fasting and postprandial serum glucose levels through increased urinary glucose excretion, ...

Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...

CHICAGO — The first trial to evaluate use of an SGLT2 inhibitor in people undergoing transcatheter aortic valve replacement showed benefit with dapagliflozin compared with standard care alone ...

In adults with HF with mildly reduced or preserved ejection fraction, dapagliflozin significantly reduced risk for CV death and worsening HF compared with placebo, with no attenuation of treatment ...

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney ...

Dapagliflozin reduced the risk of death or worsening heart failure (HF) in older patients with aortic stenosis who underwent transcatheter aortic valve implantation (TAVI), according to study ...

Individuals treated with dapagliflozin demonstrated a reduction in FPG, a secondary endpoint, from baseline at week 24: -12.5 mg/dL for dapagliflozin 2.5 mg, -18.8 mg/dL for dapagliflozin 5 mg and ...